private:envoytherapeutics
|
819526
|
May 24th, 2019 12:00AM
|
Envoy Therapeutics, Inc.
|
180
|
1.00
|
Open
|
Biotechnology
|
May 24th, 2019 03:11PM
|
May 24th, 2019 03:11PM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
Open
|
|
Open
|
555 Heritage Drive
|
Jupiter
|
FL
|
US
|
33458
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Mar 23rd, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Mar 23rd, 2017 10:51AM
|
Mar 23rd, 2017 10:51AM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Feb 17th, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Feb 16th, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Feb 15th, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Feb 14th, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Feb 13th, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Feb 12th, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Feb 11th, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
private:envoytherapeutics
|
819526
|
Feb 10th, 2018 12:00AM
|
Envoy Therapeutics, Inc.
|
176
|
2.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Started with an initial $8 million financing in October 2009, Envoy Therapeutics used a proprietary technology called bacTRAP to identify target proteins expressed in the circuitry of neurological and psychiatric diseases and then discovered and optimized drug compounds that acted on those proteins. In November 2012, Takeda Pharmaceuticals purchased Envoy for $140 million.
|
|
|
|
|
|
|
|
|
|
Envoy Therapeutics
|
|
Pharmaceuticals & Biotechnology
|